Ipsen agreed to acquire Memo Therapeutics for up to €700 million, adding potravitug, Memo’s Phase II monoclonal antibody targeting the BK virus VP1 capsid protein. The asset is aimed at BK polyomavirus associated nephropathy in kidney transplant recipients, where reactivation can undermine transplant outcomes. Potravitug received FDA fast track designation in 2023 and orphan drug designation in the EU in December 2025. Ipsen said the acquisition strengthens its rare disease pipeline and leverages transplant-focused R&D and development experience.